Related Experiment Videos
Meningoencephalitis due to penicillin-resistant Streptococcus pneumoniae
1Service de Réanimation Polyvalente, Hôpital Saint-Antoine, Paris, France.
Intensive Care Medicine
|January 1, 1992
Summary
High-dose cefotaxime is crucial for treating pneumococcal meningoencephalitis caused by resistant strains. Standard doses may not effectively clear cerebrospinal fluid infections, necessitating aggressive antibiotic therapy.
Area of Science:
- Neurology
- Infectious Diseases
- Pharmacology
Background:
- Pneumococcal meningitis is a severe infection of the brain and spinal cord membranes.
- Antibiotic resistance in Streptococcus pneumoniae complicates treatment strategies.
- Meningoencephalitis involves inflammation of both the meninges and the brain tissue.
Observation:
- A case of a 68-year-old man with pneumococcal meningoencephalitis was documented.
- The causative pneumococcal strain exhibited multi-drug resistance.
- Cerebrospinal fluid sterilization required high-dose cefotaxime, even with adequate drug levels achieved at moderate doses.
Findings:
- Moderate cefotaxime doses achieved satisfactory cerebrospinal fluid antibiotic levels but failed to sterilize the fluid.
- High-dose cefotaxime was essential to eradicate the resistant pneumococcal strain from the cerebrospinal fluid.
- This highlights the challenge of treating resistant bacterial meningitis.
Implications:
- Initial therapy for suspected pneumococcal meningitis should consider high doses of third-generation cephalosporins.
- This approach is recommended in France and globally due to rising antibiotic resistance.
- Optimizing antibiotic dosing is critical for improving patient outcomes in severe CNS infections.